To identify new risk variants for chronic lymphocytic leukemia (CLL), we conducted a genome-wide association study of 299,983 tagging SNPs, with validation in four additional series totaling 2,503 cases and 5,789 controls. We identified four new risk loci for CLL at 2q37.3 (rs757978, FARP2; odds ratio (OR) = 1.39; P = 2.11 × 10 −9 ), 8q24.21 (rs2456449; OR = 1.26; P = 7.84 × 10 −10 ), 15q21.3 (rs7169431; OR = 1.36; P = 4.74 × 10 −7 ) and 16q24.1 (rs305061; OR = 1.22; P = 3.60 × 10 −7 ). We also found evidence for risk loci at 15q25.2 (rs783540, CPEB1; OR = 1.18; P = 3.67 × 10 −6 ) and 18q21.1 (rs1036935; OR = 1.22; P = 2.28 × 10 −6 ). These data provide further evidence for genetic susceptibility to this B-cell hematological malignancy.
To identify new risk variants for chronic lymphocytic leukemia (CLL), we conducted a genome-wide association study of 299,983 tagging SNPs, with validation in four additional series totaling 2,503 cases and 5,789 controls. We identified four new risk loci for CLL at 2q37.3 (rs757978, FARP2; odds ratio (OR) = 1.39; P = 2.11 × 10 −9 ), 8q24.21 (rs2456449; OR = 1.26; P = 7.84 × 10 −10 ), 15q21.3 (rs7169431; OR = 1.36; P = 4.74 × 10 −7 ) and 16q24.1 (rs305061; OR = 1.22; P = 3.60 × 10 −7 ). We also found evidence for risk loci at 15q25.2 (rs783540, CPEB1; OR = 1.18; P = 3.67 × 10 −6 ) and 18q21.1 (rs1036935; OR = 1.22; P = 2.28 × 10 −6 ). These data provide further evidence for genetic susceptibility to this B-cell hematological malignancy.
While B-cell chronic lymphocytic leukemia (CLL) shows a strong familial risk 1 , the genetic basis of predisposition is largely unknown. We previously reported results of a genome-wide association (GWA) study of CLL based on an analysis of 299,983 tagging SNPs in 505 cases and 1,438 controls (henceforth referred to as stage 1) 2 and, through fast track analysis of SNPs with the smallest P-values, identified risk loci at 2q13, 2q37.1, 6p25.3, 11q24.1, 15q23 and 19q13. 32 (ref. 2) . We have conducted further followup analyses, making use of existing GWA data, and report four new susceptibility loci.
In stage 2, we genotyped 180 SNPs in 540 UK cases (UK replication series 1). The SNPs were chosen by a hypothesis-free strategy on the basis of P-values, excluding those correlated with an r 2 > 0.8 with previously identified association signals. After quality control, we recovered 162 SNP genotypes for 519 cases. We used publicly accessible data on 2,695 UK blood donor controls to compare genotype frequencies. In stage 3, we genotyped the 19 SNPs that showed the strongest association from combined analysis of stages 1 and 2 in two case-control series: UK replication series 2 (660 cases, 809 controls) and a Spanish replication series (424 cases, 450 controls). In stage 4, we genotyped the 10 SNPs with the strongest association from a combined analysis of stages 1-3 in a Swedish replication series (395 cases, 397 controls) ( Supplementary Fig. 1) .
The combined analysis of these data provided conclusive evidence of an association between CLL and seven SNPs (that is, P < 5.0 × 10 −7 ; Supplementary Table 1 ) mapping to five independent genomic regions. rs11668878 maps to 19q13.32, a region we previously reported to be a risk locus for CLL (defined by rs11083846) 2 . Linkage disequilibrium (LD) exists between rs11668878 and rs11083846 (r 2 = 0.27, D′ = 1.0), and conditional analysis did not provide evidence for a second disease locus (P > 0.05). Mouth-wash DNA samples were available from 89 of the cases in stage 1 and stage 2; SNP genotypes were 99% concordant with genotypes obtained from typing blood DNA. This concordance, together with the fact that the associations we identified do not map to any of the regions of the genome commonly associated with copy number variation in CLL [3] [4] [5] [6] , mitigates against Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk the possibility that our findings are influenced by bias from differential genotyping as a consequence of allelic imbalance.
Under a fixed-effects model, the strongest evidence for association to a new risk locus was attained with rs2456449, which maps to 8q24.21 at 128262163 bp (OR = 1.26, 95% confidence interval (c.i.) 1.17-1.35; P = 7.84 × 10 −10 ; P het = 0.95, I 2 = 0%; Fig. 1 and Supplementary Table 1 ). rs2466024, localizing to 128257201 bp, also provided significant evidence for the 8q24.21 association (P = 4.61 × 10 −7 ; Supplementary  Table 1 ). rs2456449 and rs2466024 are in strong LD (r 2 = 0.75, D′ = 1.0) and map to a 40-kb region of LD (128241868-128282415 bp; Fig. 2 and Supplementary Fig. 2 ). Conditional analysis provided no evidence for an independent role of rs2466024.
GWA studies have shown that the 128-130 Mb genomic interval at 8q24.21 harbors multiple independent loci with different tumor specificities: prostate (rs16901979; 128194098 bp) 7 , breast (rs13281615; 128424800 bp) 8 , colorectal and prostate (rs6983267; 128482487 bp) 9,10 , prostate (rs1447295; 128554220 bp) 11 and bladder (rs9642880; 128787250 bp) 12 cancer. The LD blocks defining these loci are distinct from the 8q24.21 CLL association signal. This is reflected in the LD metrics between rs2456449 and rs6983267 (r 2 = 0.00, D′ = 0.13), rs13281615 (r 2 = 0.00, D′ = 0.01), rs16901979 (r 2 = 0.01, D′ = 1.0), rs1447295 (r 2 = 0.04, D′ = 1.0) and rs9642880 (r 2 = 0.02, D′ = 0.19). The 8q24.21 region to which the cancer associations map is bereft of genes and predicted transcripts. rs6983267 has recently been shown to affect TCF4 binding to an enhancer for MYC, providing a mechanistic basis for this 8q24.21 association 13, 14 . It is possible that the effect of the other 8q24.21 cancer risk loci is by way of MYC through similar long-range cis-acting mechanisms. We have shown that variation in IRF4 influences CLL risk 2 . If the 8q24.21 locus influences risk through differential MYC expression, then the association is intriguing because MYC is a direct target of IRF4 in activated B-cells 15 . Although no relationship between rs2456449 genotype and MYC expression was observed in EBV-transformed lymphocytes ( Supplementary Fig. 3 ), this does not preclude a subtle effect on expression.
The second-strongest statistical evidence for an association signal was provided by rs757978, mapping to exon 9 of FARP2 at 2q37.3 (242,019,774 bp; OR = 1.39, 95% c.i. 1.25-1.56; P = 2.11 × 10 −9 ; P het = 0.13, I 2 = 43%; Fig. 1, Supplementary Fig. 2 and Supplementary Table 1 ). rs11681497, which maps to intron 4 of FARP2 (241993006 bp) and is in LD with rs757978 (r 2 = 1, D′ = 1), also provided strong evidence for the 2q37.3 association (P = 4.53 × 10 −9 ; Fig. 2) ; however, conditional analysis provided no evidence for an independent role. FARP2 is involved in signaling downstream of G protein-coupled receptors 16 . We examined whether there was a relationship between genotype and FARP2 expression in EBV-transformed lymphocytes. Data was unavailable for rs757978, but no association between rs11681497 genotype and mRNA expression level was observed ( Supplementary  Fig. 3 ). rs757978 leads to the substitution of threonine for isoleucine at amino acid 260 (T260I). As in silico analysis predicts T260I to be functionally deleterious, it is possible that the association signal at 2q37.3 is a consequence of T260I.
The third-strongest association was provided by rs305061 (OR = 1.22, 95% c.i. 1.12-1.32; P = 3.60 × 10 −7 ; P het = 0.38, I 2 = 5%; Fig. 1 and Supplementary Table 1 ), which maps within a 30-kb region of LD at 16q24.1 (84533160 bp; Fig. 2 ). rs305061 localizes 19 kb telomeric to IRF8. Variation in IRF8 represents a strong candidate for the association as IRF8 regulates αand β-interferon response. Moreover, IRF8 is involved in B-cell lineage specification, immunoglobulin rearrangement and regulation of germinal center reaction 17 . Variation at 16q24.1, defined by rs17445836, which maps 61 kb telomeric to IRF8 (84575164 bp), has recently been shown to be a risk locus for multiple sclerosis 18 . Multiple sclerosis has been reported to be associated with CLL risk 19, 20 . Although rs17445836 and rs305061 are not strongly correlated (r 2 = 0.13, D′ = 0.82), it is possible that a common genetic basis for both diseases is mediated through the same causal variant at 16q24.1.
The fourth-strongest association was identified with rs7169431, which maps to 15q21.3 (54128188 bp; OR = 1.36, 95% c.i. 1.21-1.53; P = 4.74 × 10 −7 ; P het = 0.51, I 2 = 0%; Fig. 1 and Supplementary Table 1 ). rs7169431 localizes to a 25-kb region of LD flanked by NEDD4 and RFX7 ( Fig. 2 and Supplementary Fig. 2) . Although there is no evidence for a direct role of NEDD4 in CLL, it represents a credible candidate gene because of its role in regulating viral latency and pathogenesis of EBV. Specifically, NEDD4 regulates EBV-LMP2A, which mimics signaling induced by the B-cell receptor, altering B-cell development 21 .
In addition to these four loci, there was evidence for two more disease loci, at 15q25.2 (rs783540) and 18q21.1 (rs1036935), although associations did not attain genome-wide significance (OR = 1.18, 95% c.i. 1.10-1.27; P = 3.67 × 10 −6 ; P het = 0.07, I 2 = 53% and OR = 1.22, 95% c.i. 1.12-1.32; P = 2.28 × 10 −6 , P het = 0.39, I 2 = 3%, respectively; Fig. 2 ). rs783540 localizes to intron 2 of CPEB1, which has an established role in regulating cyclin B1 during embryonic cell division and differentiation. Two genes mapping centromeric to rs1036935, CXXC1 and MBD1, are involved in gene regulation. MBD1 expression in EBV-transformed lymphocytes correlated with risk genotype (Supplementary Fig. 3) .
Although MBD1 has no documented role in CLL, it has potential to affect CLL development through translational control of MYC by means of MDBP binding 22 . CLL shows male predominance and can be classified on the basis of the presence or absence of somatic hypermutations of immunoglobulin heavy-chain variable (IGVH) genes 23, 24 , with mutated-CLL having a better prognosis. Deletion at 17p is also associated with inferior survival 25 . We assessed the relationship between age, sex, family history of B-cell malignancy, IGVH-mutation and 17p-deletion status and SNP genotypes by case-only logistic regression ( Supplementary  Table 2 ). Furthermore, we examined the influence of genotype on overall survival (stages 1 and 4) and progression-free survival (stage 1; Supplementary Table 3 ). None of the SNPs showed evidence of a relationship with age or sex (on the basis of cases from all stages). Having a family history of B-cell malignancy (stages 1, 2) was associated with a higher frequency of FARP2 rs11681497 and rs757978 risk genotypes (P = 0.031 and 0.037, respectively; Supplementary Table 2) , compatible with familial cases being enriched for genetic susceptibility. No relationship between 17p deletion status and genotype was observed (stage 1). Although there was evidence that rs305061 risk genotype was associated with worse overall survival ( Supplementary  Table 3 ), IGVH-mutation status (stages 1, 2, 4) was highly correlated with rs305061, with risk genotype correlating with unmutated-CLL (P = 0.0002; Supplementary Table 2 ). Because rs305061 maps to IRF8, this relationship is compatible with dysfunctional B-cell activation signaling being associated with possession of risk genotype.
To gain insight into the allelic architecture of predisposition to CLL, we looked for interactive effects between 2q37.3, 8q24.21, 15q21.3 and 16q24.1 variants and the previously identified loci at 2q13 (rs17483466), 2q37.1 (rs13397985), 6p25.3 (rs872071), 11q24.1 (rs735665), 15q23 (rs7176508) and 19q13.32 (rs11083846). The only evidence for an interaction between loci, albeit nonsignificant l e t t e r s after adjusting for multiple testing, was provided by rs305061 and rs7176508 (P = 0.045; Supplementary Table 4 ). The proportion of cases and controls grouped according to the number of risk alleles that they carry is detailed in Figure 3 . The distribution of risk alleles followed a normal distribution in both cases and controls, but with a shift toward a higher number of risk alleles in cases. The carrier frequencies of risk alleles are high in the European population, and hence the ten loci collectively make a substantial contribution to the development of CLL, with the population fraction ascribable to these loci being ~87%. Moreover, the risk of CLL increased with increasing numbers of variant alleles for the ten loci (OR per-allele = 1.39, 95% c.i. 1.35-1.44; P = 2.73 × 10 −88 ; Fig. 3 and Supplementary Table 5 ). Individuals with 13 or more risk alleles have a more than sevenfold increase in CLL risk compared to those with a median number of risk alleles. We estimate that the ten loci we have identified account for ~10% of the excess familial risk of CLL, assuming a polygenic model. Although the estimated effect of each of the ten risk variants we have identified may be upwardly biased due to the phenomenon referred to as the 'winners curse', ORs may be underestimates because the additive model on which analyses are based assumes equal weighting across the SNPs. The effect on susceptibility attributable to variation at the loci and the effect of the actual causal variant responsible for the association is, however, likely to be greater. Furthermore, many of the loci may carry additional risk variants, potentially including low-frequency variants with larger influence on CLL risk. Genome-wide linkage scans have provided evidence, albeit nonsignificant, for moderate-to high-penetrance susceptibility loci for CLL [26] [27] [28] . As none of the variants we have identified map to these regions of linkage, it is unlikely that any other alleles at the loci we have identified are responsible for these linkage signals.
The power of our study to detect the major common loci conferring risks of ≥1.4 (for example, rs872071) was high. Hence, we consider that there are unlikely to be many more SNPs with similar effects for alleles with frequencies >0.4 in populations of European ancestry. In contrast, we had low power to detect alleles with smaller effects and/or minor allele frequencies (MAFs) <0.1 (for example, rs7169431). By implication, variants with such profiles are likely to represent a much larger class of susceptibility loci for CLL, whether because of truly small effect sizes or submaximal LD with tagging SNPs. Furthermore, GWA-based strategies are not optimally configured to identify lowfrequency variants with potentially stronger effects. In addition, these arrays are not ideally formatted to capture copy number variants which may also affect CLL risk. Thus, it is likely that a large number of low-penetrance variants remain to be discovered. This assertion is supported by the continued excess of associations observed over those expected, in addition to the regions studied herein. Further efforts to expand the scale of GWA meta-analyses, in terms of both sample size and SNP coverage, and to increase the number of SNPs taken forward to large-scale replication may identify additional risk variants.
These results provide evidence for low-risk variants predisposing to CLL and insight into the development of this hematological malignancy. Ethnic differences in CLL risk are recognized, and it is notable that the MAF of 8q24.21 and 15q21.3 SNPs provided evidence of differences between the Spanish and the UK plus Swedish populations ( Supplementary Table 1 ). Hence, it will be interesting to explore how our findings translate to ethnically non-Western countries with substantially lower incidence rates 29 . Furthermore, the reciprocal familial risks between CLL and other B-cell malignancies 1 raises the possibility that these variants may also influence the risk of related B-cell tumors.
MeThOdS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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ONLINe MeThOdS
Initial genome-wide scan. This study describes the follow-up of a previously reported GWA of CLL 2 . Briefly, 505 cases were genotyped using HumanCNV370-Duo BeadChips (Illumina). For controls, we made use of publicly accessible HumanHap550K BeadChip genotype data generated on 1,438 individuals from the Wellcome Trust Case-Control Consortium WTCCC British 1958 Birth Cohort. Quality control metrics included removal of samples with call rates <90% and SNP assays with call rates <95%. Subjects with evidence of cryptic relatedness and non-European background were excluded from the analysis. We considered only the 299,983 autosomal SNPs with MAF >1% in cases and controls, and with no extreme evidence of departure from Hardy-Weinberg equilibrium (HWE; P > 10 −5 ) in cases or controls.
Comparison of observed and expected distributions showed little evidence for an inflation of test statistics (inflation factor λ = 1.053). 3) recruited to a study of acute leukemia conducted 1991-1996, as previously described 30 . The Spanish replication series comprised 445 cases and 450 controls. Cases were Spanish residents and were of self-reported European ancestry. Controls were obtained from the MedXen Control population cohort (Xunta de Galicia) and were matched to cases by geographic origin, age and sex.
Replication
In stage 4, we genotyped the ten SNPs showing the strongest evidence of an association from joint analysis of stages 1-3 in the Swedish replication series, comprising 304 case samples from SCALE (Scandinavian Lymphoma Etiology) 31 Data on both progression-free survival and overall survival were available for 356 stage 1 cases who participated in the UK CLL-4 trial, a randomized phase III trial established to compare the efficacy of fludarabine, chlorambucil and the combination of fludarabine plus cyclophosphamide as treatment for Binet stages B, C and A-progressive CLL 32 . Progression-free survival was defined as the survival time from the date of randomization to relapse needing further therapy, progression or death from any cause. Data on overall survival were also available for 395 of the Swedish replication series (stage 4).
In all studies the diagnosis of CLL was confirmed in accordance with the current WHO classification guidelines 33 . Ethics. Collection of blood samples and clinico-pathological information from patients and controls was undertaken with informed consent and relevant institutional ethical review board approval in accordance with the tenets of the Declaration of Helsinki.
Replication series genotyping. DNA was extracted from EDTA venous blood samples using standard methodologies and Picogreen quantified (Invitrogen). To ensure quality control of genotyping, a series of duplicate samples were genotyped in the same batches. For all SNP assays, >99% concordant results were obtained. Genotyping in UK replication 1 was performed by Sequenom MassARRAY system. We attempted to type 180 SNPs, although it was not possible to design functional assays for 18 SNPs with this technology. Details of the methodology are available on request. To exclude technical artifacts of genotyping, we included a random series of 24 samples previously genotyped using Illumina 550K HapMap arrays (Illumina). We successfully genotyped 519 unique subjects passing quality control metrics, excluding validation samples and study duplicates. Genotyping of UK replication 2 and the Swedish replication series were conducted by competitive allele-specific PCR KASPar chemistry (KBiosciences; see URLs); primer sequences and conditions available on request. Excluding validation samples and study duplicates, we genotyped 1,469 unique subjects in UK replication series 2 and 792 unique subjects in the Swedish replication series passing quality control metrics. Genotyping of Spanish samples was conducted using the Sequenom MassARRAY system in two i-Plex assays. Excluding validation samples and study duplicates, we genotyped 874 unique subjects passing quality control metrics.
IGVH mutation and 17p deletion status. IGVH mutation status was determined according to BIOMED-2 protocols as described previously 34, 35 or commercial reagents (InVivoScribe). Clonality was assessed by size discrimination of PCR products using semiautomated ABI3730xl/ABI3700 sequencers in conjunction with Genescan software (Applied Biosystems). Sequences obtained were submitted to online database IMGT/V-QUEST 36 . In accordance with published criteria, sequences with a germline identity of ≥98% were classified as unmutated, and those showing identity <98% as mutated. Deletion of 17p was defined as >10% loss in cells.
Statistical analysis.
Statistical analyses were undertaken using R (v2.3.1) and STATA (v10.0) software. Deviation of the genotype frequencies in the controls from those expected under HWE was assessed by the χ 2 -test (1 d.f.). The association between each SNP and risk of CLL was assessed by the Cochran-Armitage trend test. Odds ratios and associated 95% confidence intervals were calculated by unconditional logistic regression. Relationships between multiple SNPs showing association with CLL risk in the same region were investigated using logistic regression analysis, and the impact of additional SNPs from the same region was assessed by a likelihood-ratio test.
Associations by sex, age and mutation status were examined by logistic regression in case-only analyses. The combined effect of pairs of loci identified with risk was investigated by logistic regression modeling; evidence for interactive effects between SNPs assessed by a likelihood ratio test. The OR and trend test for increasing numbers of deleterious alleles was estimated by counting two for a homozygote and one for a heterozygote assuming equal weights.
Meta-analysis was conducted using standard methods 37 . Cochran's Q-statistic to test for heterogeneity 37 and the I 2 statistic 38 to quantify the proportion of the total variation due to heterogeneity were calculated. Large heterogeneity is typically defined as I 2 ≥ 75%. The population attributable fraction was estimated from 1
(1 − p)OR 1 + p 2 OR 2 , p is the population allele frequency, and OR 1 and OR 2 are the ORs associated with hetero-and homozygosity, respectively. The sibling relative risk attributable to a given SNP was calculated using the formula 39 : where p is the population frequency of the minor allele, q = 1 − p, and r 1 and r 2 are the relative risks (estimated as OR) for heterozygotes and rare homozygotes, relative to common homozygotes. Assuming a multiplicative interaction, the proportion of the familial risk attributable to a SNP was calculated as log λ* / log λ 0 , where λ 0 is the overall familial relative risk estimated from epidemiological studies, assumed to be 7.25 (ref. 1).
Bioinformatics. We used Haploview software (v3.2) to infer the LD structure of the genome in the regions containing loci associated with disease risk. We applied two in silico algorithms, PolyPhen and SIFT, to predict the impact of nonsynonymous SNPs on protein function.
Relationship between SNP genotype and expression levels.
To examine for a relationship between SNP genotype and expression levels of MYC, FARP2, NEDD4, MBD1 and CPEB1 in lymphocytes, we made use of publicly available expression data generated from analysis of 90 European ancestry-derived Epstein-Barr virus-transformed lymphoblastoid cell lines using Sentrix Human-6 Expression BeadChips (Illumina) 40, 41 . Online recovery of data was performed using WGAViewer Version 1.25 Software. Differences in the distribution of levels of mRNA expression between SNP genotypes were compared using a Wilcoxon-type test for trend 42 .
